Bloomberg News (11/30, Armstrong) reports
Johnson & Johnson announced it would allow generic-drug manufacturers to
"make and distribute copies of its HIV medicine Prezista [darunavir] in
sub-Saharan Africa and poor countries." The New Brunswick, New Jersey,
pharmaceutical company said it "won't enforce patent claims" against
drugmakers that produce generic copies of its antiretroviral drug. However, the
J&J agreement "says that generics manufacturers can only distribute
the medicine for patients living in the African and least-developed
countries." According to the WHO, about "34.2 million people
worldwide are infected with HIV, including 22.9 million in Africa."
Reuters (11/30, Hirschler) notes that J&J
already has one such agreement under which Durban, South Africa-based Aspen
Pharmacare produces darunavir at a $2.22 daily price. AFP (11/30) also covers the J&J
announcement.
DIA Daily is a digest of the most important news selected from
thousands of sources by the editors of BulletinHealthcare. The presence of
content or advertising does not endorse, nor imply endorsement of, any products
or services by the Drug Information Association. Neither BulletinHealthcare nor
the Drug Information Association is liable for the use of or reliance on any
information contained in this briefing.
If you would like more information about, or
have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.
Click here to check your membership status.
Drug Information
Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare
| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191
No comments:
Post a Comment